Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Ac-DEVD-CHO

Ac-DEVD-CHO
Contact us for more batch information
Select Batch
Purity:98.69%
Resource Download

Ac-DEVD-CHO

Catalog No. TQ0146Cas No. 169332-60-9
Ac-DEVD-CHO is a specific Caspase-3 inhibitor (Ki: 230 pM).Ac-DEVD-CHO has an inhibitory effect in SLNT-induced apoptosis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$68In Stock
2 mg$108In Stock
5 mg$237In Stock
10 mg$349In Stock
25 mg$592In Stock
50 mg$845In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Ac-DEVD-CHO"

Product Introduction

Bioactivity
Description
Ac-DEVD-CHO is a specific Caspase-3 inhibitor (Ki: 230 pM).Ac-DEVD-CHO has an inhibitory effect in SLNT-induced apoptosis.
In vitro
The addition of Ac-DEVD-CHO significantly prevents SLNT-induced apoptosis (from 32.91% decreases to 15.88% while NC and Ac-DEVD-CHO groups are 6.45%, and 7.77%, respectively) [2].
Ac-DEVD-CHO (10 μmol/L) partially blocks the effect of SIN-induced apoptosis and reduces the number of apoptotic nuclei. These effects of SIN are blocked by the caspase-3 inhibitor Ac-DEVD-CHO. Camptothecin (4 μM), a positive control, increases caspase-3 activity, which is also blocked by Ac-DEVD-CHO.[3]
In vivo
One hundred and two male C57BL/6 mice were subjected to cecal ligation and puncture (CLP, a model of polymicrobial sepsis) or sham operation. The animals were assigned into three equal groups (n=34) according to the random number table: sham group, model group, and caspase-3 inhibitor (CI) group. Thirty minutes before CLP, Ac-DEVD-CHO (4 μg/g) was injected subcutaneously in the CI group. The levels of blood urea nitrogen (BUN) and creatinine (Cr) were determined, and the concentrations of tumor necrosis factor-α (TNF-α), interleukins (IL-6 and IL-10) were measured by enzyme-linked immunosorbent assay (ELISA), the renal cell apoptosis rate was determined by flow cytometry and the expression of caspase-3 mRNA was determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) at 6, 12 and 24 hours after operation. The 4-day and 7-day survival rates of three groups of mice were observed. Results: Compared with the sham group, the concentrations of serum BUN, TNF-α, IL-6, IL-10, and the renal cell apoptosis rates, the caspase-3 mRNA expression were increased significantly at all time points after CLP, the concentrations of serum Cr were increased significantly at 6 hours, with the 4-day and 7-day survival rates were decreased significantly. Compared with the model group, in the CI group, the concentrations of serum BUN were decreased significantly at all time points after operation and those of Cr were decreased significantly at 6 hours, then restored to those of the sham group at 12 hours and 24 hours; the concentrations of serum TNF-α, IL-6 were decreased and those of IL-10 elevated significantly at all time points. (P<0.05); the renal cell apoptosis rate and the expression of caspase-3 mRNA were decreased significantly at all time points. The 4-day survival rate of the CI group was improved (80% vs. 20%), but that of the 7-day did not change (20% vs. 20%).[4]
Chemical Properties
Molecular Weight502.47
FormulaC20H30N4O11
Cas No.169332-60-9
Storage & Solubility Information
Storagekeep away from moisture,store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
H2O: 50.25 mg/mL (100 mM)
Solution Preparation Table
H2O
1mg5mg10mg50mg
1 mM1.9902 mL9.9508 mL19.9017 mL99.5084 mL
5 mM0.3980 mL1.9902 mL3.9803 mL19.9017 mL
10 mM0.1990 mL0.9951 mL1.9902 mL9.9508 mL
20 mM0.0995 mL0.4975 mL0.9951 mL4.9754 mL
50 mM0.0398 mL0.1990 mL0.3980 mL1.9902 mL
100 mM0.0199 mL0.0995 mL0.1990 mL0.9951 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords